Activity‐Directed Synthesis of Inhibitors of the p53/hDM2 Protein–Protein Interaction

Abstract Protein–protein interactions (PPIs) provide a rich source of potential targets for drug discovery and biomedical science research. However, the identification of structural‐diverse starting points for discovery of PPI inhibitors remains a significant challenge. Activity‐directed synthesis (ADS), a function‐driven discovery approach, was harnessed in the discovery of the p53/hDM2 PPI. Over two rounds of ADS, 346 microscale reactions were performed, with prioritisation on the basis of the activity of the resulting product mixtures. Four distinct and novel series of PPI inhibitors were discovered that, through biophysical characterisation, were shown to have promising ligand efficiencies. It was thus shown that ADS can facilitate ligand discovery for a target that does not have a defined small‐molecule binding site, and can provide distinctive starting points for the discovery of PPI inhibitors.

[1]  M. Pirrung,et al.  PREPARATION AND SCREENING AGAINST ACETYLCHOLINESTERASE OF A NON-PEPTIDE INDEXED COMBINATORIAL LIBRARY , 1995 .

[2]  Danna Zhou,et al.  d. , 1840, Microbial pathogenesis.

[3]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[4]  Shanghai Yu,et al.  SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. , 2014, Cancer research.

[5]  Gerhard Wagner,et al.  A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. , 2004, Biochemistry.

[6]  A. Maguire,et al.  Modern Organic Synthesis with α-Diazocarbonyl Compounds. , 2015, Chemical reviews.

[7]  O. Koch,et al.  Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes , 2015, Angewandte Chemie.

[8]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[9]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[10]  J. Murray,et al.  Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. , 2014, Journal of medicinal chemistry.

[11]  Jason E Gestwicki,et al.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. , 2018, Current opinion in chemical biology.

[12]  J. Bajorath,et al.  Recent Advances in Scaffold Hopping. , 2017, Journal of medicinal chemistry.

[13]  A. ADoefaa,et al.  ? ? ? ? f ? ? ? ? ? , 2003 .

[14]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[15]  K. Zak,et al.  A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction. , 2016, ACS chemical biology.

[16]  S. Warriner,et al.  2-O-alkylated para-benzamide α-helix mimetics: the role of scaffold curvature. , 2012, Organic & biomolecular chemistry.

[17]  Dennis G. Gillingham,et al.  Catalytic X-H insertion reactions based on carbenoids. , 2013, Chemical Society reviews.

[18]  Adam Nelson,et al.  Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists , 2015, Angewandte Chemie.

[19]  Jeffrey P. Plante,et al.  Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction† †Electronic supplementary information (ESI) available: Synthetic procedures, protein expression and FP assays. See DOI: 10.1039/b908207g Click here for additional data file. , 2009, Chemical communications.

[20]  Binh Vu,et al.  Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.

[21]  Xin Huang,et al.  Rational design and binding mode duality of MDM2-p53 inhibitors. , 2013, Journal of medicinal chemistry.

[22]  Oliver Zerbe,et al.  Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2004 .

[23]  Ajit Jadhav,et al.  Fluorescence polarization assays in high-throughput screening and drug discovery: a review , 2016, Methods and applications in fluorescence.

[24]  Peter Willett,et al.  Maximum common subgraph isomorphism algorithms for the matching of chemical structures , 2002, J. Comput. Aided Mol. Des..

[25]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[26]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[27]  O. Koch,et al.  Strukturbasierte Entwicklung von Protein-Protein-Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden , 2015 .

[28]  Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor. , 2014, ACS medicinal chemistry letters.

[29]  Binh Vu,et al.  Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. , 2013, ACS medicinal chemistry letters.

[30]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.

[31]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[32]  Dima Kozakov,et al.  Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein-Protein Interfaces , 2012, J. Chem. Inf. Model..

[33]  Yi-Lin Huang,et al.  Synthetic fermentation of bioactive non-ribosomal peptides without organisms, enzymes or reagents. , 2014, Nature chemistry.

[34]  H. Davies,et al.  Reactions of metallocarbenes derived from N-sulfonyl-1,2,3-triazoles. , 2014, Chemical Society reviews.

[35]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[36]  C. Ottmann,et al.  Modulators of protein-protein interactions. , 2014, Chemical reviews.

[37]  Alexander Dömling,et al.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. , 2010, Angewandte Chemie.

[38]  A. Padwa,et al.  Übergangsmetallkatalysierte Reaktionen von α-Diazocarbonylverbindungen – Einfluß der Liganden auf die Chemoselektivität† , 1994 .

[39]  J. Canon,et al.  Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.

[40]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[41]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[42]  Christine L. Andrews,et al.  Nanoscale synthesis and affinity ranking , 2018, Nature.

[43]  G. Maggiora,et al.  Molecular similarity in medicinal chemistry. , 2014, Journal of medicinal chemistry.

[44]  M. Williamson Using chemical shift perturbation to characterise ligand binding. , 2013, Progress in nuclear magnetic resonance spectroscopy.

[45]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[46]  M. Noble,et al.  Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy , 2011, Chemical biology & drug design.

[47]  Nir London,et al.  Druggable protein-protein interactions--from hot spots to hot segments. , 2013, Current opinion in chemical biology.

[48]  D. Austin,et al.  Ligand Effects on the Chemoselectivity of Transition Metal Catalyzed Reactions of α‐Diazo Carbonyl Compounds , 1994 .

[49]  H. Davies,et al.  Catalytic Asymmetric C−H Activation of Alkanes and Tetrahydrofuran , 2000 .

[50]  D. Miller,et al.  Synthetic applications of the O-H insertion reactions of carbenes and carbenoids derived from diazocarbonyl and related diazo compounds , 1995 .

[51]  J. Canon,et al.  Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction. , 2014, Journal of medicinal chemistry.

[52]  M. Doyle,et al.  The influence of ligands on dirhodium(II) on reactivity and selectivity in metal carbene reactions , 2007 .

[53]  Adam Nelson,et al.  Efficient discovery of bioactive scaffolds by activity-directed synthesis , 2014, Nature Chemistry.

[54]  P. Alam ‘A’ , 2021, Composites Engineering: An A–Z Guide.

[55]  P. Alam ‘N’ , 2021, Composites Engineering: An A–Z Guide.

[56]  Min Liu,et al.  Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. , 2010, Journal of molecular biology.

[57]  Shanghai Yu,et al.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. , 2009, Journal of medicinal chemistry.

[58]  S. Warriner,et al.  N-alkylated oligoamide alpha-helical proteomimetics. , 2010, Organic & biomolecular chemistry.